Abstract
Agent with both great blood clotting activity and bone regeneration ability is deserved to replace conventional bone wax. Recently, hydroxyapatite (HA) has attracted interests from researchers with its both hemostatic and bone healing functions. In present work, the blood clotting activity comparisons of HA to other potential bone repairing materials including calcium silicate, calcium combined attapulgite, calcium tripolyphosphate, and chitosan were carried out to show HA as a recommended hemostatic component to replace bone wax. In addition, the impacts of HA synthesis routes on its blood clotting activity were evaluated, indicating increase of surface area as well as active $Ca^{2+}$ of HA can greatly enhance blood clotting. With these attributes, it is expected HA can be a promising component in fabricating hemostatic materials in orthopedic applications as alternatives to bone wax.
Introduction
During orthopedic surgeries, surgeons frequently use "bone wax" (traditionally a beeswax-based compound) to control bleeding from bone surfaces. While effective at stopping blood flow, bone wax is non-biodegradable and can interfere with natural bone healing, sometimes triggering inflammation or infection. The search for a "bioactive" hemostat—one that stops bleeding and then actively assists in bone regeneration—has led researchers to evaluate various inorganic ceramics. Hydroxyapatite (HA), a mineral naturally found in human bone, is a leading candidate for this role due to its inherent biocompatibility and dual-threat capability as both a hemostat and a scaffold for bone growth.
Materials and Methods
The research team compared HA against several other potential bone-repairing materials, including inorganic salts like calcium silicate ($CaSiO_3$), calcium-combined attapulgite, and calcium tripolyphosphate ($Ca_5(P_3O_{10})_2$). The materials were synthesized using a hydrothermal method and characterized via Transmission Electron Microscopy (TEM) to observe their distinct physical structures.
To measure clotting efficiency, the team used the Blood Clotting Index (BCI). In this test, human blood is placed in contact with the material; a lower BCI value indicates better clotting performance, as it represents less free, un-clotted blood remaining in the sample.
Key Results and Discussion
Comparative Performance
The study found that HA achieved the lowest BCI among all tested inorganic salts, significantly outperforming calcium silicate and calcium tripolyphosphate. This quantitative data establishes HA as a superior hemostatic component compared to other common bone-repairing ceramics.
Mechanisms of Action
HA’s effectiveness is driven by both chemical and physical properties:
- Calcium Ion Release: HA releases $Ca^{2+}$ ions, which are essential cofactors in the body's natural coagulation cascade. Variants synthesized with higher calcium-to-phosphorus ratios showed even faster clotting due to rapid ion release.
- Surface Area: Morphology is critical. Mesoporous HA (HA-HMP) showed a BCI of approximately 25, compared to standard HA which sat closer to 40. The increased surface area provides more sites for plasma protein adsorption and ion exchange.
- Synergy with Chitosan: While HA alone is a potent hemostat, combining it with biopolymers like chitosan—which aggregates red blood cells—creates a multi-pronged attack on surgical bleeding.
Conclusion
Hydroxyapatite represents a highly promising alternative to traditional bone wax, offering a unique combination of hemostatic efficiency and bone-healing bioactivity. While these in vitro results are compelling, future research must focus on in vivo testing to confirm performance in living circulatory systems and to optimize the material's mechanical handling for surgical applications.
Summary updated